Article

FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.

Department of Orthopaedics, Case Western Reserve University, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
Human Molecular Genetics (Impact Factor: 6.68). 11/2008; 18(2):227-40. DOI: 10.1093/hmg/ddn339
Source: PubMed

ABSTRACT Activating mutations in FGFR3 cause achondroplasia and thanatophoric dysplasia, the most common human skeletal dysplasias. In these disorders, spinal canal and foramen magnum stenosis can cause serious neurologic complications. Here, we provide evidence that FGFR3 and MAPK signaling in chondrocytes promote synchondrosis closure and fusion of ossification centers. We observed premature synchondrosis closure in the spine and cranial base in human cases of homozygous achondroplasia and thanatophoric dysplasia as well as in mouse models of achondroplasia. In both species, premature synchondrosis closure was associated with increased bone formation. Chondrocyte-specific activation of Fgfr3 in mice induced premature synchondrosis closure and enhanced osteoblast differentiation around synchondroses. FGF signaling in chondrocytes increases Bmp ligand mRNA expression and decreases Bmp antagonist mRNA expression in a MAPK-dependent manner, suggesting a role for Bmp signaling in the increased bone formation. The enhanced bone formation would accelerate the fusion of ossification centers and limit the endochondral bone growth. Spinal canal and foramen magnum stenosis in heterozygous achondroplasia patients, therefore, may occur through premature synchondrosis closure. If this is the case, then any growth-promoting treatment for these complications of achondroplasia must precede the timing of the synchondrosis closure.

0 Bookmarks
 · 
125 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bioarchaeologists rely on accurate estimations of age-at-death. Clearly, some pathological conditions are associated with gross morphological changes in the skeleton that could impact the effectiveness of age-at-death estimation (i.e. methods based on the pelvis, fourth rib, dental attrition, and cranial stenosis). The magnitude of this problem has not been widely studied due to a paucity of pathological skeletons of known age. We assessed age-at death for three individuals affected by bone dysplasias (achondroplasia, residual rickets, osteogenesis imperfecta) using cementum annulations and several osseous age indicators. We predicted osseous indicators that are based on gross morphological changes would yield age estimates discrepant from the cementochronology. Results demonstrated considerable differences in age estimates between morphological and histological techniques suggesting a need for additional research on the effects of pathology on the accuracy of morphological methods. Conversely, we addressed the proposition that cementum annulations will be inappropriate for age estimation in cases of chronic and severe rhino-maxillary infection and periodontitis. We assessed age-at-death for one individual with leprosy and found no indication the disease process affected cementum formation or preservation. The results of this research indicate the potential value of cementochronology in cases where skeletal pathological conditions constrain the usefulness of traditional age estimation approaches.
    04/2014; DOI:10.1016/j.ijpp.2014.04.001
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Fibroblast growth factors (FGFs) and their receptors (FGFRs) play significant roles in vertebrate organogenesis and morphogenesis. FGFR3 is a negative regulator of chondrogenesis and multiple mutations with constitutive activity of FGFR3 result in achondroplasia, one of the most common dwarfisms in humans, but the molecular mechanism remains elusive. In this study, we found that chondrocyte-specific deletion of BMP type I receptor a (Bmpr1a) rescued the bone overgrowth phenotype observed in Fgfr3 deficient mice by reducing chondrocyte differentiation. Consistently, using in vitro chondrogenic differentiation assay system, we demonstrated that FGFR3 inhibited BMPR1a-mediated chondrogenic differentiation. Furthermore, we showed that FGFR3 hyper-activation resulted in impaired BMP signaling in chondrocytes of mouse growth plates. We also found that FGFR3 inhibited BMP-2- or constitutively activated BMPR1-induced phosphorylation of Smads through a mechanism independent of its tyrosine kinase activity. We found that FGFR3 facilitate BMPR1a to degradation through Smurf1-mediated ubiquitination pathway. We demonstrated that down-regulation of BMP signaling by BMPR1 inhibitor dorsomorphin led to the retardation of chondrogenic differentiation, which mimicks the effect of FGF-2 on chondrocytes and BMP-2 treatment partially rescued the retarded growth of cultured bone rudiments from thanatophoric dysplasia type II mice. Our findings reveal that FGFR3 promotes the degradation of BMPR1a, which plays an important role in the pathogenesis of FGFR3-related skeletal dysplasia.
    Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 07/2014; DOI:10.1016/j.bbamcr.2014.03.011 · 5.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Achondroplasia (ACH), the most common form of human dwarfism, is caused by an activating autosomal dominant mutation in the fibroblast growth factor receptor-3 (FGFR3) gene. Genetic overexpression of C-type natriuretic peptide (CNP), a positive regulator of endochondral bone growth, prevents dwarfism in mouse models of ACH. However, administration of exogenous CNP is compromised by its rapid clearance in vivo through receptor-mediated and proteolytic pathways. Using in vitro approaches, we developed modified variants of human CNP, resistant to proteolytic degradation by neutral endopeptidase (NEP), that retain the ability to stimulate signaling downstream of the CNP receptor, natriuretic peptide receptor B (NPR B). The variants tested in vivo demonstrated significantly longer serum half-lives than native CNP. Subcutaneous administration of one of these CNP variants, BMN 111, resulted in correction of the dwarfism phenotype in a mouse model of ACH and overgrowth of the axial and appendicular skeletons in wild-type mice without observable changes in trabecular and cortical bone architecture. Moreover, significant growth plate widening that translated into accelerated bone growth, at hemodynamically tolerable doses, was observed in juvenile cynomolgus monkeys that had received daily subcutaneous administrations of BMN 111. BMN 111 was well tolerated and represents a promising new approach for treatment of patients with ACH. The American Society for Pharmacology and Experimental Therapeutics.
    Journal of Pharmacology and Experimental Therapeutics 02/2015; DOI:10.1124/jpet.114.218560 · 3.89 Impact Factor

Preview

Download
0 Downloads
Available from